Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Creating a novel drug has always been a risky endeavor for biopharmaceutical companies. Developers and investors face ...

A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be ...

A new study found a link between SGLT-2 inhibitors and a significantly lower risk of dementia in people with diabetes. Here's ...

GLP-1 receptor agonist use was associated with a reduced risk of progressing to cirrhosis and related complications in ...

In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

All of those patients were either taking oral diabetes medications SGLT-2 or DPP-4 inhibitors for their condition. SGLT-2 helps the kidneys remove excess glucose from the body through urine ...

It seems like a day doesn’t go by without another positive finding for the glucagon-like peptide 1 (GLP-1) receptoragonist ...

Su Yu-cheng (right)shares his experience of serving as the flag bearer for the Chinese Kendo team during the opening ceremony ...